AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
Charlie Blackie-Kelly | October 31, 2025 | News story | | AAX Biotech, Daiichi Sankyo, Opti-mAb, Seqitope
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic partnership with Daiichi Sankyo, a global leader in antibody-drug conjugates (ADCs). The collaboration will focus on evaluating AAX Biotech’s Opti-mAb antibody platform.
AAX Biotech has developed two proprietary antibody platforms, Seqitope and Opti-mAb, designed to address key challenges in antibody engineering and therapeutic design. These platforms aim to enable the development of more effective and stable biologic treatments.
Opti-mAb combines high-resolution epitope mapping with high-throughput capabilities and enhances the stability of inherently unstable single-chain variable fragment (scFv) antibodies – enabling their application in modalities such as CAR T cell therapies.
Under the agreement, researchers at the Daiichi Sankyo Research Institute in Munich, Germany, will assess the performance of the Opti-mAb platform and explore opportunities for further collaboration to advance treatments targeting unmet medical needs.
“For AAX Biotech, collaborating with a company with the scale and reputation of Daiichi Sankyo represents a tremendous validation of our innovative approach,” says Maria Lisa Knudsen, CEO of AAX Biotech. “This provides us with the opportunity to showcase the power of Opti-mAb in collaboration with a truly global leader in pharmaceutical innovation.”
Related Content
AAX Biotech and ToxoTech partner to develop next-gen biotherapeutics for neurological disorders
AAX Biotech, a biotech company specialising in next-generation antibody therapeutics, has entered a strategic partnership …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
